Skip to main content
Hossein Borghaei, DO, Oncology, Philadelphia, PA

HosseinBorghaeiDO

Oncology Philadelphia, PA

Hematologic Oncology, Thoracic Cancer

Director, Thoracic Medical Oncology

Dr. Borghaei is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Borghaei's full profile

Already have an account?

  • Office

    333 Cottman Ave
    # Fox
    Philadelphia, PA 19111
    Phone+1 215-728-6900
    Fax+1 215-728-3639

Summary

  • Dr. Hossein Borghaei is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Temple University Hospital and Fox Chase Cancer Center-American Oncologic Hospital. He received his medical degree from Philadelphia College of Osteopathic Medicine and has been in practice 21 years. He specializes in hematologic oncology and thoracic cancer and is experienced in immunotherapy, non-small cell lung cancer, urologic oncology, biomedical research, and combined modality therapy.

Education & Training

  • Temple University Hospital-Fox Chase Cancer Center
    Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
  • Graduate Hospital
    Graduate HospitalResidency, Internal Medicine, 1997 - 2000
  • Philadelphia College of Osteopathic Medicine
    Philadelphia College of Osteopathic MedicineClass of 1996

Certifications & Licensure

  • PA State Medical License
    PA State License 1997 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?
    Should First-Line Dual Checkpoint Blockade Be Used for NSCLC with Specific Mutations?October 24th, 2024
  • Warning on Use of Sotorasib After ICI in Lung Cancer
    Warning on Use of Sotorasib After ICI in Lung CancerJune 1st, 2023
  • Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR Mutations
    Pleural, Pericardial Effusion cfDNA Detects Actionable EGFR MutationsJanuary 19th, 2023
  • Join now to see all

Professional Memberships